Anthony Henry Dickenson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anthony Henry Dickenson has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
- Kirsty Bannister
Department of Life Sciences, Imperial College London, South Kensington, United Kingdom
11 shared publications - Ryan Patel
Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK
8 shared publications Rie Suzuki
University College London
5 shared publications- Mateusz Kucharczyk
Central Modulation of Pain, Institute of Psychiatry, Psychology and Neuroscience, King’s College London , London SE1 1UL , UK
4 shared publications - Stephen Brendan McMahon
Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom
4 shared publications - Diane Derrien
University College London
3 shared publications
Latest Publications
- Open Access
- 9 January 2024
- Published by Wolters Kluwer Health in Pain
- Vol. 165 (9) , 1978-1989
A back-translational study of descending interactions with the induction of hyperalgesia by high-frequency electrical stimulation in rats and humans
In humans and animals, high-frequency electrocutaneous stimulation (HFS) induces an “early long-term potentiation-like” sensitisation, where synaptic plasticity is underpinned by an ill-defined interaction between peripheral input and central modulatory processes. The relative contributions of these processes to the initial pain or nociceptive response likely differ from those that underpin development of the heightened response. To investigate the impact of HFS-induced hyperalgesia on pain and nociception in perception and neural terms, respectively, and to explore the impact of descending inhibitory pathway activation on the development of HFS-induced hyperalgesia, we performed parallel studies utilising identical stimuli to apply HFS concurrent to (1) a conditioned pain modulation paradigm during psychophysical testing in healthy humans or (2) a diffuse noxious inhibitory controls paradigm during in vivo electrophysiological recording of spinal neurones in healthy anaesthetised rats. High-frequency electrocutaneous stimulation alone induced enhanced perceptual responses to pinprick stimuli in cutaneous areas secondary to the area of electrical stimulation in humans and increased the excitability of spinal neurones which exhibited stimulus intensity–dependent coded responses to pinprick stimulation in a manner that tracked with human psychophysics, supporting their translational validity. Application of a distant noxious conditioning stimulus during HFS did not alter perceived primary or secondary hyperalgesia in humans or the development of primary or secondary neuronal hyperexcitability in rats compared with HFS alone, suggesting that, upon HFS-response initiation in a healthy nervous system, excitatory signalling escapes inhibitory control. Therefore, in this model, dampening facilitatory mechanisms rather than augmenting top-down inhibitions could prevent pain development.
- 9 January 2024
- Published by Wolters Kluwer Health in Pain
- Vol. 165 (9) , 1978-1989
Open AccessA back-translational study of descending interactions with the induction of hyperalgesia by high-frequency electrical stimulation in rats and humans
In humans and animals, high-frequency electrocutaneous stimulation (HFS) induces an “early long-term potentiation-like” sensitisation, where synaptic plasticity is underpinned by an ill-defined interaction between peripheral input and central modulatory processes. The relative contributions of these processes to the initial pain or nociceptive response likely differ from those that underpin development of the heightened response. To investigate the impact of HFS-induced hyperalgesia on pain and nociception in perception and neural terms, respectively, and to explore the impact of descending inhibitory pathway activation on the development of HFS-induced hyperalgesia, we performed parallel studies utilising identical stimuli to apply HFS concurrent to (1) a conditioned pain modulation paradigm during psychophysical testing in healthy humans or (2) a diffuse noxious inhibitory controls paradigm during in vivo electrophysiological recording of spinal neurones in healthy anaesthetised rats. High-frequency electrocutaneous stimulation alone induced enhanced perceptual responses to pinprick stimuli in cutaneous areas secondary to the area of electrical stimulation in humans and increased the excitability of spinal neurones which exhibited stimulus intensity–dependent coded responses to pinprick stimulation in a manner that tracked with human psychophysics, supporting their translational validity. Application of a distant noxious conditioning stimulus during HFS did not alter perceived primary or secondary hyperalgesia in humans or the development of primary or secondary neuronal hyperexcitability in rats compared with HFS alone, suggesting that, upon HFS-response initiation in a healthy nervous system, excitatory signalling escapes inhibitory control. Therefore, in this model, dampening facilitatory mechanisms rather than augmenting top-down inhibitions could prevent pain development.
- Open Access
- 1 January 2024
- Published by Walter de Gruyter GmbH in Scandinavian Journal of Pain
- Vol. 24 (1)
Pain perception while listening to thrash heavy metal vs relaxing music at a heavy metal festival – the CoPainHell study – a factorial randomized non-blinded crossover trial
Objectives: Music festivals are often a source of joy, but also a risk of injury. While previous studies suggest music can relieve pain, its effect has not been tested in festival settings, nor has the effect of high-energy vs soothing music been compared. We hypothesized that guests at a heavy metal music festival would experience less pain when listening to thrash heavy metal compared to relaxing music, with the effect being influenced by music preference and increased with higher alcohol intake. Methods: This factorial randomized non-blinded crossover trial assessed pain during a 5°C cold pressor test (CPT) at a heavy metal festival. Participants were randomized to listen to either Slayer’s “Raining Blood” or Enya’s “Orinoco Flow” during their first CPT, and the opposite song during the second CPT. The primary outcome was pain during the CPT, assessed as area under the curve (AUC). Music fondness and breath alcohol concentration (BrAC) were measured before each CPT. Results: Forty-five adults, aged 19–58 years, were included, and completed both CPTs. Significantly more pain was reported while listening to Enya (AUC 1,155 [IQR 588–1,507]) vs Slayer (AUC 975 [IQR 682–1,492]) ( p = 0.048). Higher BrAC was associated with decreased pain ( p = 0.042). Participants with higher fondness of Enya experienced significantly more pain than those who liked the song less ( p = 0.021). Fondness of Slayer had no effect on pain perception ( p = 0.7). Conclusion: Listening to thrash heavy metal, specifically “Raining Blood” by Slayer during painful stimuli results in lower pain intensity than listening to relaxing music in the form of “Orinoco Flow” by Enya. The findings’ impact on pain in a clinical setting should be explored.
- 1 January 2024
- Published by Walter de Gruyter GmbH in Scandinavian Journal of Pain
- Vol. 24 (1)
Open AccessPain perception while listening to thrash heavy metal vs relaxing music at a heavy metal festival – the CoPainHell study – a factorial randomized non-blinded crossover trial
Objectives: Music festivals are often a source of joy, but also a risk of injury. While previous studies suggest music can relieve pain, its effect has not been tested in festival settings, nor has the effect of high-energy vs soothing music been compared. We hypothesized that guests at a heavy metal music festival would experience less pain when listening to thrash heavy metal compared to relaxing music, with the effect being influenced by music preference and increased with higher alcohol intake. Methods: This factorial randomized non-blinded crossover trial assessed pain during a 5°C cold pressor test (CPT) at a heavy metal festival. Participants were randomized to listen to either Slayer’s “Raining Blood” or Enya’s “Orinoco Flow” during their first CPT, and the opposite song during the second CPT. The primary outcome was pain during the CPT, assessed as area under the curve (AUC). Music fondness and breath alcohol concentration (BrAC) were measured before each CPT. Results: Forty-five adults, aged 19–58 years, were included, and completed both CPTs. Significantly more pain was reported while listening to Enya (AUC 1,155 [IQR 588–1,507]) vs Slayer (AUC 975 [IQR 682–1,492]) ( p = 0.048). Higher BrAC was associated with decreased pain ( p = 0.042). Participants with higher fondness of Enya experienced significantly more pain than those who liked the song less ( p = 0.021). Fondness of Slayer had no effect on pain perception ( p = 0.7). Conclusion: Listening to thrash heavy metal, specifically “Raining Blood” by Slayer during painful stimuli results in lower pain intensity than listening to relaxing music in the form of “Orinoco Flow” by Enya. The findings’ impact on pain in a clinical setting should be explored.
- 8 October 2023
- Published by Index Copernicus in Ból
- Vol. 24 (3) , 21-34
REPRINTED WITH PERMISSION OF IASP – PAIN 164 (2023) 3–13: Ambroxol for neuropathic pain: hiding in plain sight?
- 8 October 2023
- Published by Index Copernicus in Ból
- Vol. 24 (3) , 21-34
REPRINTED WITH PERMISSION OF IASP – PAIN 164 (2023) 3–13: Ambroxol for neuropathic pain: hiding in plain sight?
- Open Access
- 15 December 2022
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (6) , 1264-1279
Nerve injury increases native CaV2.2 trafficking in dorsal root ganglion mechanoreceptors
Neuronal N-type (CaV2.2) voltage-gated calcium channels are essential for neurotransmission from primary afferent terminals in the dorsal horn. In this study, we have used a knockin mouse containing CaV2.2 with an inserted extracellular hemagglutinin tag (CaV2.2_HA), to visualise the pattern of expression of endogenous CaV2.2 in dorsal root ganglion (DRG) neurons and their primary afferents in the dorsal horn. We examined the effect of partial sciatic nerve ligation (PSNL) and found an increase in CaV2.2_HA only in large and medium dorsal root ganglion neurons and also in deep dorsal horn synaptic terminals. Furthermore, there is a parallel increase in coexpression with GFRα1, present in a population of low threshold mechanoreceptors, both in large DRG neurons and in their terminals. The increased expression of CaV2.2_HA in these DRG neurons and their terminals is dependent on the presence of the auxiliary subunit α2δ-1, which is required for channel trafficking to the cell surface and to synaptic terminals, and it likely contributes to enhanced synaptic transmission at these synapses following PSNL. By contrast, the increase in GFRα1 is not altered in α2δ-1–knockout mice. We also found that following PSNL, there is patchy loss of glomerular synapses immunoreactive for CaV2.2_HA and CGRP or IB4, restricted to the superficial layers of the dorsal horn. This reduction is not dependent on α2δ-1 and likely reflects partial deafferentation of C-nociceptor presynaptic terminals. Therefore, in this pain model, we can distinguish 2 different events affecting specific DRG terminals, with opposite consequences for CaV2.2_HA expression and function in the dorsal horn.
- 15 December 2022
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (6) , 1264-1279
Open AccessNerve injury increases native CaV2.2 trafficking in dorsal root ganglion mechanoreceptors
Neuronal N-type (CaV2.2) voltage-gated calcium channels are essential for neurotransmission from primary afferent terminals in the dorsal horn. In this study, we have used a knockin mouse containing CaV2.2 with an inserted extracellular hemagglutinin tag (CaV2.2_HA), to visualise the pattern of expression of endogenous CaV2.2 in dorsal root ganglion (DRG) neurons and their primary afferents in the dorsal horn. We examined the effect of partial sciatic nerve ligation (PSNL) and found an increase in CaV2.2_HA only in large and medium dorsal root ganglion neurons and also in deep dorsal horn synaptic terminals. Furthermore, there is a parallel increase in coexpression with GFRα1, present in a population of low threshold mechanoreceptors, both in large DRG neurons and in their terminals. The increased expression of CaV2.2_HA in these DRG neurons and their terminals is dependent on the presence of the auxiliary subunit α2δ-1, which is required for channel trafficking to the cell surface and to synaptic terminals, and it likely contributes to enhanced synaptic transmission at these synapses following PSNL. By contrast, the increase in GFRα1 is not altered in α2δ-1–knockout mice. We also found that following PSNL, there is patchy loss of glomerular synapses immunoreactive for CaV2.2_HA and CGRP or IB4, restricted to the superficial layers of the dorsal horn. This reduction is not dependent on α2δ-1 and likely reflects partial deafferentation of C-nociceptor presynaptic terminals. Therefore, in this pain model, we can distinguish 2 different events affecting specific DRG terminals, with opposite consequences for CaV2.2_HA expression and function in the dorsal horn.
- Open Access
A back-translational study of descending interactions with central mechanisms of hyperalgesia induced by high frequency stimulation in rat and human
In humans and animals, high frequency electrocutaneous stimulation (HFS) may produce an ‘early long-term potentiation-like’ sensitisation. Peripheral and central modulatory processes are proposed to play a role. To explore the impact of descending inhibitory pathway activation on the development of HFS-induced hyperalgesia, we concurrently applied HFS with i) a conditioned pain modulation (CPM) paradigm during psychophysical testing in humans, or ii) a diffuse noxious inhibitory controls (DNIC) paradigm during in vivo electrophysiological recording of spinal neurones in anaesthetised animals in parallel studies that utilised identical stimuli. HFS induced enhanced perceptual responses to pin-prick stimuli in cutaneous areas secondary to the area of stimulation in humans and heightened the excitability of spinal neurones in rats (which exhibited stimulus intensity dependent coded responses to pin-prick stimulation in a manner that tracked with human psychophysics), where we also observed indicators of increased central neuronal hyperexcitability. In humans, a HFS(+CPM) paradigm did not alter primary or secondary hyperalgesia, and the area and pain intensity of secondary hyperalgesia did not correlate with temporal summation of pain or CPM magnitude, while in rats application of a DNIC paradigm concurrent to HFS did not impact the development of neuronal hyperexcitability. Concordance between human and rat data supports their translational validity. Our finding that excitatory signalling exceeds inhibitory controls suggests that dampening facilitatory mechanisms may be a preferable strategy for certain chronic pain states. If facilitatory mechanisms dominate, our data could explain why enhancing activity in descending inhibitory controls is not sufficient to induce pain relief in vulnerable patients.
Open AccessA back-translational study of descending interactions with central mechanisms of hyperalgesia induced by high frequency stimulation in rat and human
In humans and animals, high frequency electrocutaneous stimulation (HFS) may produce an ‘early long-term potentiation-like’ sensitisation. Peripheral and central modulatory processes are proposed to play a role. To explore the impact of descending inhibitory pathway activation on the development of HFS-induced hyperalgesia, we concurrently applied HFS with i) a conditioned pain modulation (CPM) paradigm during psychophysical testing in humans, or ii) a diffuse noxious inhibitory controls (DNIC) paradigm during in vivo electrophysiological recording of spinal neurones in anaesthetised animals in parallel studies that utilised identical stimuli. HFS induced enhanced perceptual responses to pin-prick stimuli in cutaneous areas secondary to the area of stimulation in humans and heightened the excitability of spinal neurones in rats (which exhibited stimulus intensity dependent coded responses to pin-prick stimulation in a manner that tracked with human psychophysics), where we also observed indicators of increased central neuronal hyperexcitability. In humans, a HFS(+CPM) paradigm did not alter primary or secondary hyperalgesia, and the area and pain intensity of secondary hyperalgesia did not correlate with temporal summation of pain or CPM magnitude, while in rats application of a DNIC paradigm concurrent to HFS did not impact the development of neuronal hyperexcitability. Concordance between human and rat data supports their translational validity. Our finding that excitatory signalling exceeds inhibitory controls suggests that dampening facilitatory mechanisms may be a preferable strategy for certain chronic pain states. If facilitatory mechanisms dominate, our data could explain why enhancing activity in descending inhibitory controls is not sufficient to induce pain relief in vulnerable patients.
- Open Access
- 19 May 2022
- Published by Frontiers Media SA in Frontiers in Pain Research
- Vol. 3, 913232
The Life and Times of Stephen B. McMahon (1954–2021)
Steve McMahon, always known as Mac, was a remarkable scientist with a breadth of knowledge that spanned many areas of neuroscience and physiology but with a major emphasis on pain and spinal cord injury. Many scientists use a number of techniques in their career but Mac had a range that spanned in vivo and in vitro electrophysiology, immunohistochemistry, behavior, human psychophysics, pharmacology and molecular biology, all carried out to the highest standards. This range and his prolific output lead to an h index of 113 at the time of writing. His studies were innovative, ground breaking and always interesting. Mac trained a whole generation of young scientists, was a wonderful mentor and collaborator encouraging all who were around him. Attending a conference with Mac was a delight. His questions were always incisive but kind; the evening socializing was engaging but no one explained how he could be the last to leave but always on time for the morning session. In workshops and at advisory boards he was always on the ball and his scientific knowledge and wisdom were dispensed freely and with honesty. Mac loved to debate; such discourse was handled in a sympathetic fashion and although he was normally right he was prepared to change his position should the data or force of argument be persuasive. Mac had profound effects on the science of pain and spinal cord injury through his scientific output and wisdom for over 30 years and his legacy will live on. Mac, a Londoner through and through, did an undergraduate degree in Physiology in Leeds in 1973 and stayed on to gain a Ph.D. in visceral sensory processing. In 1981, he moved back to London and joined the group of Pat Wall at University College London. He continued to work with Pat over many years and Pat moved his laboratory to join Mac when he left UCL as Emeritus. By this time Mac had set up his own research group from 1984 at St Thomas' Hospital Medical School and in 1996 became the Sherrington Prof of Physiology at Kings College London where he remained for the rest of his career. Pat and Mac both loved in vivo electrophysiology and brought their scientific expertise together in a series of imaginative experiments to understand how peripheral inputs and targets modulate the spinal processing of nociceptive inputs. Mac worked on a wide range of topics with spinal cord repair and pain processing being the main themes. Mac loved to innovate and as his career flourished added more cutting-edge techniques to his group, enabling him to tackle scientific problems in a multi-disciplinary manner. He was instrumental in paving the way for anti-NGF therapies from a whole series of studies on the roles of neurotrophins in the sensory nervous system; the proof of concept for the analgesic actions of anti-NGF was ultimately validated by human trials. Unfortunately, side-effects on joint function have prevented their clinical use. His work became more and more translational. From studying inflammatory mediators in rat and human skin to combining neuronal activity in rodents to human psychophysical measures in humans, remarkable similarities were noted. And in one of his final studies, the paper was able to shed much needed light on the mechanisms behind neuromodulation for pain control. Mac was a wonderful collaborator – the Dickenson and McMahon laboratories published 9 papers together where we had an idea and needed to marshal different techniques to succeed. Off we went – Ph.D. students and post-docs went from lab to lab and the studies raced ahead. Never a conflict or worry and the studies ranged from downstream mediators to cancer pain mechanisms to human sensory processing. But the highlight of the collaborations was the establishment of the London Pain Consortium that went global and became the Wellcome Trust Pain Consortium. It all started when the Trust recognized the need for studies in systems for harnessing molecular and genetic advances in pain. Mac seized the day and a one-off 5 year Integrative Physiology Initiative Award was gained with eight PIs in London institutions. This was followed by two prestigious Strategic Awards and a Ph.D. program. For more than 15 years, collaborations were struck and the final personnel involved were Mac, ourselves, Irene Tracey, Allan Basbaum, Andrew Todd, Giandomenico Iannetti and Frank Porreca was a collaborator. A group of friends who all respected each other and with a thirst for scientific progress with Mac leading the team. The Consortium published innumerable papers, ran summer schools in the UK, Spain and Denmark, organized seminars, and the Ph.D. program produced a generation of excellent young scientists. The alumni of the Wellcome pain consortium are now establishing their own pain laboratories across the world. Mac managed to integrate his scientific friendships with family life both with gatherings at his home in Muswell Hill London and where possible traveling with family. He is survived by his wife Sara, an academic pediatrician, daughter Emma and sons Arun and Jasso. Mac was such a respected scientist, a trailblazer, a wonderful friend and colleague and a delight to be with. He leaves a strong scientific legacy of scientific publications and the many people he has trained and inspired in the pain and neuroscience communities. Both authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Keywords: pain, McMahon, life and times, obituary, spinal injury Citation: Dickenson AH and Bennett DLH (2022) The Life and Times of Stephen B. McMahon (1954–2021). Front. Pain Res. 3:913232. doi: 10.3389/fpain.2022.913232 Received: 05 April 2022; Accepted: 25 April 2022; Published: 19 May 2022. Edited by: Reviewed by: Copyright © 2022 Dickenson and Bennett. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Anthony H. Dickenson, anthony.dickenson@ucl.ac.uk In Memoriam: This paper is dedicated to the memory of Stephen B. McMahon (1954-2021).
- 19 May 2022
- Published by Frontiers Media SA in Frontiers in Pain Research
- Vol. 3, 913232
Open AccessThe Life and Times of Stephen B. McMahon (1954–2021)
Steve McMahon, always known as Mac, was a remarkable scientist with a breadth of knowledge that spanned many areas of neuroscience and physiology but with a major emphasis on pain and spinal cord injury. Many scientists use a number of techniques in their career but Mac had a range that spanned in vivo and in vitro electrophysiology, immunohistochemistry, behavior, human psychophysics, pharmacology and molecular biology, all carried out to the highest standards. This range and his prolific output lead to an h index of 113 at the time of writing. His studies were innovative, ground breaking and always interesting. Mac trained a whole generation of young scientists, was a wonderful mentor and collaborator encouraging all who were around him. Attending a conference with Mac was a delight. His questions were always incisive but kind; the evening socializing was engaging but no one explained how he could be the last to leave but always on time for the morning session. In workshops and at advisory boards he was always on the ball and his scientific knowledge and wisdom were dispensed freely and with honesty. Mac loved to debate; such discourse was handled in a sympathetic fashion and although he was normally right he was prepared to change his position should the data or force of argument be persuasive. Mac had profound effects on the science of pain and spinal cord injury through his scientific output and wisdom for over 30 years and his legacy will live on. Mac, a Londoner through and through, did an undergraduate degree in Physiology in Leeds in 1973 and stayed on to gain a Ph.D. in visceral sensory processing. In 1981, he moved back to London and joined the group of Pat Wall at University College London. He continued to work with Pat over many years and Pat moved his laboratory to join Mac when he left UCL as Emeritus. By this time Mac had set up his own research group from 1984 at St Thomas' Hospital Medical School and in 1996 became the Sherrington Prof of Physiology at Kings College London where he remained for the rest of his career. Pat and Mac both loved in vivo electrophysiology and brought their scientific expertise together in a series of imaginative experiments to understand how peripheral inputs and targets modulate the spinal processing of nociceptive inputs. Mac worked on a wide range of topics with spinal cord repair and pain processing being the main themes. Mac loved to innovate and as his career flourished added more cutting-edge techniques to his group, enabling him to tackle scientific problems in a multi-disciplinary manner. He was instrumental in paving the way for anti-NGF therapies from a whole series of studies on the roles of neurotrophins in the sensory nervous system; the proof of concept for the analgesic actions of anti-NGF was ultimately validated by human trials. Unfortunately, side-effects on joint function have prevented their clinical use. His work became more and more translational. From studying inflammatory mediators in rat and human skin to combining neuronal activity in rodents to human psychophysical measures in humans, remarkable similarities were noted. And in one of his final studies, the paper was able to shed much needed light on the mechanisms behind neuromodulation for pain control. Mac was a wonderful collaborator – the Dickenson and McMahon laboratories published 9 papers together where we had an idea and needed to marshal different techniques to succeed. Off we went – Ph.D. students and post-docs went from lab to lab and the studies raced ahead. Never a conflict or worry and the studies ranged from downstream mediators to cancer pain mechanisms to human sensory processing. But the highlight of the collaborations was the establishment of the London Pain Consortium that went global and became the Wellcome Trust Pain Consortium. It all started when the Trust recognized the need for studies in systems for harnessing molecular and genetic advances in pain. Mac seized the day and a one-off 5 year Integrative Physiology Initiative Award was gained with eight PIs in London institutions. This was followed by two prestigious Strategic Awards and a Ph.D. program. For more than 15 years, collaborations were struck and the final personnel involved were Mac, ourselves, Irene Tracey, Allan Basbaum, Andrew Todd, Giandomenico Iannetti and Frank Porreca was a collaborator. A group of friends who all respected each other and with a thirst for scientific progress with Mac leading the team. The Consortium published innumerable papers, ran summer schools in the UK, Spain and Denmark, organized seminars, and the Ph.D. program produced a generation of excellent young scientists. The alumni of the Wellcome pain consortium are now establishing their own pain laboratories across the world. Mac managed to integrate his scientific friendships with family life both with gatherings at his home in Muswell Hill London and where possible traveling with family. He is survived by his wife Sara, an academic pediatrician, daughter Emma and sons Arun and Jasso. Mac was such a respected scientist, a trailblazer, a wonderful friend and colleague and a delight to be with. He leaves a strong scientific legacy of scientific publications and the many people he has trained and inspired in the pain and neuroscience communities. Both authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Keywords: pain, McMahon, life and times, obituary, spinal injury Citation: Dickenson AH and Bennett DLH (2022) The Life and Times of Stephen B. McMahon (1954–2021). Front. Pain Res. 3:913232. doi: 10.3389/fpain.2022.913232 Received: 05 April 2022; Accepted: 25 April 2022; Published: 19 May 2022. Edited by: Reviewed by: Copyright © 2022 Dickenson and Bennett. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Anthony H. Dickenson, anthony.dickenson@ucl.ac.uk In Memoriam: This paper is dedicated to the memory of Stephen B. McMahon (1954-2021).
- 28 October 2021
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 134 (3) , 245-259
Neuropharmacological basis for multimodal analgesia in chronic pain
Managing chronic pain remains a major unmet clinical challenge. Patients can be treated with a range of interventions, but pharmacotherapy is the most common. These include opioids, antidepressants, calcium channel modulators, sodium channel blockers, and nonsteroidal anti-inflammatory drugs. Many of these drugs target a particular mechanism; however, chronic pain in many diseases is multifactorial and induces plasticity throughout the sensory neuroaxis. Furthermore, comorbidities such as depression, anxiety, and sleep disturbances worsen quality of life. Given the complexity of mechanisms and symptoms in patients, it is unsurprising that many fail to achieve adequate pain relief from a single agent. The efforts to develop novel drug classes with better efficacy have not always proved successful; a multimodal or combination approach to analgesia is an important strategy in pain control. Many patients frequently take more than one medication, but high-quality evidence to support various combinations is often sparse. Ideally, combining drugs would produce synergistic action to maximize analgesia and reduce side effects, although sub-additive and additive analgesia is still advantageous if additive side-effects can be avoided. In this review, we discuss pain mechanisms, drug actions, and the rationale for mechanism-led treatment selection. Abbreviations: COX – cyclooxygenase, CGRP – calcitonin gene-related peptide, CPM – conditioned pain modulation, NGF – nerve growth factor, NNT – number needed to treat, NMDA – N-methyl-d-aspartate, NSAID – nonsteroidal anti-inflammatory drugs, TCA – tricyclic antidepressant, SNRI – serotonin-noradrenaline reuptake inhibitor, QST – quantitative sensory testing.
- 28 October 2021
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 134 (3) , 245-259
Neuropharmacological basis for multimodal analgesia in chronic pain
Managing chronic pain remains a major unmet clinical challenge. Patients can be treated with a range of interventions, but pharmacotherapy is the most common. These include opioids, antidepressants, calcium channel modulators, sodium channel blockers, and nonsteroidal anti-inflammatory drugs. Many of these drugs target a particular mechanism; however, chronic pain in many diseases is multifactorial and induces plasticity throughout the sensory neuroaxis. Furthermore, comorbidities such as depression, anxiety, and sleep disturbances worsen quality of life. Given the complexity of mechanisms and symptoms in patients, it is unsurprising that many fail to achieve adequate pain relief from a single agent. The efforts to develop novel drug classes with better efficacy have not always proved successful; a multimodal or combination approach to analgesia is an important strategy in pain control. Many patients frequently take more than one medication, but high-quality evidence to support various combinations is often sparse. Ideally, combining drugs would produce synergistic action to maximize analgesia and reduce side effects, although sub-additive and additive analgesia is still advantageous if additive side-effects can be avoided. In this review, we discuss pain mechanisms, drug actions, and the rationale for mechanism-led treatment selection. Abbreviations: COX – cyclooxygenase, CGRP – calcitonin gene-related peptide, CPM – conditioned pain modulation, NGF – nerve growth factor, NNT – number needed to treat, NMDA – N-methyl-d-aspartate, NSAID – nonsteroidal anti-inflammatory drugs, TCA – tricyclic antidepressant, SNRI – serotonin-noradrenaline reuptake inhibitor, QST – quantitative sensory testing.
- 26 April 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (13) , 1635-1637
Why are sodium channel modulators not yet pharmacotherapeutic trailblazers for neuropathic pain?
Despite a number of pharmacological agents with various modes of action and the possibilty of local or systemic administration, the efficacy of these agents in patients with nerve injury leads much...
- 26 April 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (13) , 1635-1637
Why are sodium channel modulators not yet pharmacotherapeutic trailblazers for neuropathic pain?
Despite a number of pharmacological agents with various modes of action and the possibilty of local or systemic administration, the efficacy of these agents in patients with nerve injury leads much...
- Open Access
The Stage-Specific Plasticity of Descending Modulatory Controls in a Rodent Model of Cancer-Induced Bone Pain
Pain resulting from metastatic bone disease is a major unmet clinical need. Studying spinal processing in rodent models of cancer pain is desirable since the percept of pain is influenced in part by modulation at the level of the transmission system in the dorsal horn of the spinal cord. Here, a rodent model of cancer-induced bone pain (CIBP) was generated following syngeneic rat mammary gland adenocarcinoma cell injection in the tibia of male Sprague Dawley rats. Disease progression was classified as “early” or “late” stage according to bone destruction. Even though wakeful CIBP rats showed progressive mechanical hypersensitivity, subsequent in vivo electrophysiological measurement of mechanically evoked deep dorsal horn spinal neuronal responses revealed no change. Rather, a dynamic reorganization of spinal neuronal modulation by descending controls was observed, and this was maladaptive only in the early stage of CIBP. Interestingly, this latter observation corresponded with the degree of damage to the primary afferents innervating the cancerous tissue. Plasticity in the modulation of spinal neuronal activity by descending control pathways reveals a novel opportunity for targeting CIBP in a stage-specific manner. Finally, the data herein have translational potential since the descending control pathways measured are present also in humans.
Open AccessThe Stage-Specific Plasticity of Descending Modulatory Controls in a Rodent Model of Cancer-Induced Bone Pain
Pain resulting from metastatic bone disease is a major unmet clinical need. Studying spinal processing in rodent models of cancer pain is desirable since the percept of pain is influenced in part by modulation at the level of the transmission system in the dorsal horn of the spinal cord. Here, a rodent model of cancer-induced bone pain (CIBP) was generated following syngeneic rat mammary gland adenocarcinoma cell injection in the tibia of male Sprague Dawley rats. Disease progression was classified as “early” or “late” stage according to bone destruction. Even though wakeful CIBP rats showed progressive mechanical hypersensitivity, subsequent in vivo electrophysiological measurement of mechanically evoked deep dorsal horn spinal neuronal responses revealed no change. Rather, a dynamic reorganization of spinal neuronal modulation by descending controls was observed, and this was maladaptive only in the early stage of CIBP. Interestingly, this latter observation corresponded with the degree of damage to the primary afferents innervating the cancerous tissue. Plasticity in the modulation of spinal neuronal activity by descending control pathways reveals a novel opportunity for targeting CIBP in a stage-specific manner. Finally, the data herein have translational potential since the descending control pathways measured are present also in humans.
- Open Access
The stage specific plasticity of descending modulatory controls in a rodent model of cancer induced bone pain
Pain resulting from metastatic bone disease is a major unmet clinical need. Studying spinal processing in rodent models of cancer pain is desirable since the percept of pain is influenced in part by modulation at the level of the transmission system in the dorsal horn of the spinal cord. Here a rodent model of cancer induced bone pain (CIBP) was generated following syngenic rat mammary gland adenocarcinoma cell injection in the tibia of male Sprague Dawley rats. Disease progression was classified as ‘early’ or ‘late’ stage according to bone destruction. Even though wakeful CIBP rats showed progressive mechanical hypersensitivity, subsequent in vivo electrophysiological measurement of mechanically evoked deep dorsal horn spinal neuronal responses revealed no change. Rather, a dynamic reorganization of spinal neuronal modulation by descending controls was observed, and this was maladaptive only in the early stage of CIBP. Interestingly, this latter observation corresponded with the degree of damage to the primary afferents innervating the cancerous tissue. Plasticity in the modulation of spinal neuronal activity by descending control pathways reveals a novel opportunity for targeting CIBP in a stage-specific manner. Finally, the data herein has translational potential since the descending control pathways measured are present also in man. Simple Summary: The mechanisms that underlie pain resulting from metastatic bone disease remain elusive. This translates to a clinical and socioeconomic burden; targeted therapy is not possible, and patients do not receive adequate analgesic relief. Complicating matters is the heterogeneous nature of metastatic bone disease. Early stage cancers are molecularly very different to their late stage counterparts and so too is the pain associated with infant and advanced tumours. Thus, analgesic approaches should differ according to disease stage. In this article we demonstrate that a unique form of brain inhibitory control responsible for modulation of incoming pain signals at the level of the spinal cord changes with the progression of bone tumours, This corresponds with the degree of damage to the primary afferents innervating the cancerous tissue. Plasticity in the modulation of spinal neuronal activity by descending control pathways reveals a novel opportunity for targeting bone cancer pain in a stage-specific manner.
Open AccessThe stage specific plasticity of descending modulatory controls in a rodent model of cancer induced bone pain
Pain resulting from metastatic bone disease is a major unmet clinical need. Studying spinal processing in rodent models of cancer pain is desirable since the percept of pain is influenced in part by modulation at the level of the transmission system in the dorsal horn of the spinal cord. Here a rodent model of cancer induced bone pain (CIBP) was generated following syngenic rat mammary gland adenocarcinoma cell injection in the tibia of male Sprague Dawley rats. Disease progression was classified as ‘early’ or ‘late’ stage according to bone destruction. Even though wakeful CIBP rats showed progressive mechanical hypersensitivity, subsequent in vivo electrophysiological measurement of mechanically evoked deep dorsal horn spinal neuronal responses revealed no change. Rather, a dynamic reorganization of spinal neuronal modulation by descending controls was observed, and this was maladaptive only in the early stage of CIBP. Interestingly, this latter observation corresponded with the degree of damage to the primary afferents innervating the cancerous tissue. Plasticity in the modulation of spinal neuronal activity by descending control pathways reveals a novel opportunity for targeting CIBP in a stage-specific manner. Finally, the data herein has translational potential since the descending control pathways measured are present also in man. Simple Summary: The mechanisms that underlie pain resulting from metastatic bone disease remain elusive. This translates to a clinical and socioeconomic burden; targeted therapy is not possible, and patients do not receive adequate analgesic relief. Complicating matters is the heterogeneous nature of metastatic bone disease. Early stage cancers are molecularly very different to their late stage counterparts and so too is the pain associated with infant and advanced tumours. Thus, analgesic approaches should differ according to disease stage. In this article we demonstrate that a unique form of brain inhibitory control responsible for modulation of incoming pain signals at the level of the spinal cord changes with the progression of bone tumours, This corresponds with the degree of damage to the primary afferents innervating the cancerous tissue. Plasticity in the modulation of spinal neuronal activity by descending control pathways reveals a novel opportunity for targeting bone cancer pain in a stage-specific manner.